Integrative transcriptomics and metabolomics explore the mechanism of kamepferol on improving non-alcoholic steatohepatitis
Transcriptomics combined with metabolomics were performed to investigate the alterations in genes and metabolites expression after kaempferol treatment in mice with high-fat diet induced NASH. The results showed that kaempferol reduced the level of alanine transaminase (ALT), low density lipoprotein cholesterol (LDL), total cholesterol (TC) in serum and triglyceride (TG) and lipid droplets and inflammatory cell infiltration in liver. Two hundreds seventy seven differential expressed genes (DEGs) were identified through liver transcriptomics and the five most obvious DEGs were CYP2b9, Cyp4a12b, Mup17, Mup7 and Mup16 indicated HFD induced in fatty acid degradation, ribosome, glyoxylic acid and dicarboxylic acid metabolism. Nine serum metabolites (methylcysteine, L-tryptophan, adrenic acid, D-2-hydroxyglutaric acid, tartaric acid, p-cresol sulfate, L-alanine, L-tryosine and glutaconic acid) and 3 liver differential metabolites (gallic acid, γ-lindenic acid and L-phenylalanine) were also identified while pathways were mainly involved in phenylalanine, tyrosine and tryptophan biosyntheses and phenylalanine metabolism. Integrating transcriptomics and metabolomics analyses indicated that kaempferol possess the ability to improve NASH associated with energy metabolism, lipid metabolism, oxidative stress and inflammation-related pathways. This study provides a powerful means of multi-omics data integration and reveals potent therapy and biomarkers for kaempferol.